EurekaMag.com logo
+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Animal models for postmenopausal osteoporosis



Animal models for postmenopausal osteoporosis



Reproduction Nutrition Development 34(3): 221-236



Osteoporosis is a disease characterized by low bone mass, microarchitectural deterioration of bone tissue leading to enhanced bone fragility, and a consequent increase in fracture risk. In humans estrogen deficiency following menopause is associated with a more or less intense osteopenia. In some subjects, such a decrease in bone mass induces osteoporosis. Several animal models (ovariectomized female dogs, pigs and monkeys) are used to study the etiology, prophylaxis and treatment for osteoporosis. Nevertheless, the changes in bone metabolism following estrogen deficiency are very similar in rats and humans. Thus, the ovariectomized rat is the most frequently used model for such studies.

(PDF emailed within 1 workday: $29.90)

Accession: 002301533

Download citation: RISBibTeXText



Related references

Animal models for glucocorticoid-induced postmenopausal osteoporosis: An updated review. Biomedicine & PharmacoTherapy 84(): 438-446, 2016

Studies On Postmenopausal Osteoporosis. Ii. Effect Of Testosterone And Acth Loading On The Urinary Excretion Of 17-Ketosteroid Fractions In Postmenopausal Osteoporosis. Acta Medica Academiae Scientiarum Hungaricae 20: 237-243, 1964

Studies On Postmenopausal Osteoporosis. 3. Total Serum Cholesterol Level In Postmenopausal Osteoporosis. Acta Medica Academiae Scientiarum Hungaricae 20: 245-247, 1964

Studies On Postmenopausal Osteoporosis. I. Urinary Excretion Of 17-Ketosteroid Fractions In Postmenopausal Osteoporosis. Acta Medica Academiae Scientiarum Hungaricae 20: 233-236, 1964

Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocrine Reviews 23(4): 529-539, 2002

Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocrine Reviews 23(4): 560-569, 2002

Reasons for discontinuating osteoporosis treatment Results from the Spanish compliance osteoporosis study in postmenopausal osteoporosis. Calcified Tissue International 72(4): 385, April, 2003

The bone regenerative effects of fucosterol in in vitro and in vivo models of postmenopausal osteoporosis. Molecular Nutrition & Food Research 58(6): 1249-1257, 2015

The correlation between postmenopausal osteoporosis and inflammatory periodontitis regarding bone loss in experimental models. Experimental Animals 61(2): 183-187, 2012

Baseline characteristics and reasons for initiating osteoporosis treatment Results from the Spanish compliance osteoporosis study in postmenopausal osteoporosis. Calcified Tissue International 72(4): 384, April, 2003

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocrine Reviews 23(4): 524-528, 2002

Meta-analyses of therapies for postmenopausal osteoporosis. VII. Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocrine Reviews 23(4): 552-559, 2002

Patients knowledge of osteoporosis Results from the Spanish compliance osteoporosis study in postmenopausal osteoporosis. Calcified Tissue International 72(4): 427-428, April, 2003

Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis. Endocrine Reviews 23(4): 540-551, 2002

Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis. Endocrine Reviews 23(4): 517-523, 2002